1 Daikeler T, Regenass S, Heijnen I, Tyndall A, Vogt T. ANCA und assoziierte Erkrankungen. Swiss Med Forum 2010;10(50):871–874.
2 Sinico RA, Radice A. Antineutrophil Cytoplasmic Antibodies (ANCA) Testing: Detection Methods and Clinical Application. Clin Exp Rheumatol 2014;32(3 Suppl 82):112–7.
3 Yates M, Watts R. ANCA-associated vasculitis. Clinical Medicine 2017;17(No 1):60–4.
4 Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases 2016;75:1583–1594.
5 Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA associated renal vasculitis. N Engl J Med 363:211–220.
6 Jayne DRW, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA‐associated systemic vasculitis with persistent disease activity. QJ Med 2000;93:433–439.
7 Pearce FA, Hubbard RB, Grainge MJ, Watts RA, Abhishek A, Lanyon PC. Can granulomatosis with polyangiitis be diagnosed earlier in primary care? A case-control study. QJ Med 2018;39–45.
8 Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 2010;69:1934–1939.
9 Kemna MJ, Damoiseaux J, Austen J, Winkens B, Peters J, van Paassen P, et al. ANCA as a Predictor of Relapse: Useful in Patients with Renal Involvement but not in Patients with Nonrenal Disease. J Am Soc Nephrol 2015;26:537–542.